UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 10-Q


             [x] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

                For the quarterly period ended September 2, 2000
                                               -----------------

                                       OR

            [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

          For the transition period from _____________ to _____________


                         Commission file number 1-11479


                                  E-Z-EM, Inc.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)


                    Delaware                            11-1999504
         -------------------------------            -------------------
         (State or other jurisdiction of             (I.R.S. Employer
          incorporation or organization)            Identification No.)


         717 Main Street, Westbury, New York              11590
      ----------------------------------------      -------------------
      (Address of principal executive offices)          (Zip Code)


                                 (516) 333-8230
             ------------------------------------------------------
               Registrant's telephone number, including area code


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days.

                                 Yes [X]  No [ ]


As of October 12, 2000,  there were  4,013,390  shares of the  issuer's  Class A
Common Stock  outstanding  and 5,861,283  shares of the issuer's  Class B Common
Stock outstanding.


                                  Page 1 of 20
                            Exhibit Index on Page 19
<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

                                      INDEX
                                      -----


Part 1:  Financial Information                                           Page
-------  ---------------------                                           ----


    Item 1.  Financial Statements


       Consolidated Balance Sheets - September 2, 2000 and
          June 3, 2000                                                   3 - 4


       Consolidated Statements of Earnings - thirteen weeks
          ended September 2, 2000 and August 28, 1999                      5


       Consolidated Statement of Stockholders' Equity and
          Comprehensive Income - thirteen weeks ended
          September 2, 2000                                                6


       Consolidated Statements of Cash Flows - thirteen weeks
          ended September 2, 2000 and August 28, 1999                    7 - 8


       Notes to Consolidated Financial Statements                        9 - 13


    Item 2.  Management's Discussion and Analysis of Financial
                    Condition and Results of Operations                 14 - 17


    Item 3.  Quantitative and Qualitative Disclosures About
                    Market Risk                                         17 - 18


Part II:  Other Information
--------  -----------------


    Item 6.  Exhibits and Reports on Form 8-K                             19


                                       -2-
<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

                           CONSOLIDATED BALANCE SHEETS
                                 (in thousands)


                                                       September 2,   June 3,
              ASSETS                                      2000          2000
                                                         -------      -------
                                                       (unaudited)   (audited)

CURRENT ASSETS
    Cash and cash equivalents                            $ 3,620      $ 5,583
    Debt and equity securities                            14,364        8,051
    Accounts receivable, principally
       trade, net                                         20,922       22,256
    Inventories                                           25,366       26,856
    Other current assets                                   5,065        4,530
                                                         -------      -------

          Total current assets                            69,337       67,276

PROPERTY, PLANT AND EQUIPMENT - AT COST,
    less accumulated depreciation and
    amortization                                          20,158       21,721

COST IN EXCESS OF FAIR VALUE OF NET ASSETS
    ACQUIRED, less accumulated amortization                  404          407

INTANGIBLE ASSETS, less accumulated
    amortization                                           1,420        2,151

DEBT AND EQUITY SECURITIES                                 2,571        4,067

OTHER ASSETS                                               5,036        3,463
                                                         -------      -------

                                                         $98,926      $99,085
                                                         =======      =======

The accompanying notes are an integral part of these statements.


                                       -3-
<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

                           CONSOLIDATED BALANCE SHEETS
                 (in thousands, except share and per share data)


                                                      September 2,      June 3,
    LIABILITIES AND STOCKHOLDERS' EQUITY                  2000           2000
                                                        --------       --------
                                                      (unaudited)      (audited)

CURRENT LIABILITIES
    Notes payable                                       $  1,067       $  1,080
    Current maturities of long-term debt                     101            103
    Accounts payable                                       5,761          6,384
    Accrued liabilities                                    6,771          7,798
    Accrued income taxes                                     742            477
                                                        --------       --------

          Total current liabilities                       14,442         15,842

LONG-TERM DEBT, less current maturities                      439            453

OTHER NONCURRENT LIABILITIES                               2,623          2,756
                                                        --------       --------

          Total liabilities                               17,504         19,051
                                                        --------       --------

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' EQUITY
    Preferred stock, par value $.10 per
       share - authorized, 1,000,000 shares;
       issued, none
    Common stock
       Class A (voting), par value $.10
          per share - authorized, 6,000,000
          shares; issued and outstanding
          4,014,269 shares at September 2,
          2000 and 4,015,111 shares at June
          3, 2000 (excluding 38,987 and
          38,145 shares held in treasury at
          September 2, 2000 and June 3, 2000,
          respectively)                                      401            401
       Class B (non-voting), par value
          $.10 per share - authorized,
          10,000,000 shares; issued and
          outstanding 5,891,265 shares at
          September 2, 2000 and 5,909,277
          shares at June 3, 2000 (excluding
          334,585 and 313,748 shares held in
          treasury at September 2, 2000 and
          June 3, 2000, respectively)                        589            591
    Additional paid-in capital                            20,393         20,521
    Retained earnings                                     61,694         59,852
    Accumulated other comprehensive income (loss)         (1,655)        (1,331)
                                                        --------       --------

          Total stockholders' equity                      81,422         80,034
                                                        --------       --------

                                                        $ 98,926       $ 99,085
                                                        ========       ========

The accompanying notes are an integral part of these statements.


                                      -4-
<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

                       CONSOLIDATED STATEMENTS OF EARNINGS
                                   (unaudited)
                      (in thousands, except per share data)


                                                      Thirteen weeks ended
                                                  ----------------------------
                                                  September 2,     August 28,
                                                     2000            1999
                                                   --------        --------

Net sales                                          $ 27,304        $ 27,197

Cost of goods sold                                   15,201          15,114
                                                   --------        --------

      Gross profit                                   12,103          12,083
                                                   --------        --------

Operating expenses
  Selling and administrative                          9,330           8,337
  Loss on sale of subsidiary and
    related assets                                      872
  Research and development                            1,272           1,201
                                                   --------        --------

    Total operating expenses                         11,474           9,538
                                                   --------        --------

      Operating profit                                  629           2,545

Other income (expense)
  Interest income                                       226             145
  Interest expense                                      (71)            (61)
  Other, net                                             18              81
                                                   --------        --------

      Earnings before income taxes                      802           2,710

Income tax provision (benefit)                       (1,040)            912
                                                   --------        --------

      NET EARNINGS                                 $  1,842        $  1,798
                                                   ========        ========

Earnings per common share
  Basic                                            $    .19        $    .18
                                                   ========        ========

  Diluted                                          $    .18        $    .18
                                                   ========        ========

Weighted average common shares
  Basic                                               9,915          10,073
                                                   ========        ========

  Diluted                                            10,245          10,228
                                                   ========        ========

The accompanying notes are an integral part of these statements.


                                       -5-
<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

     CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY AND COMPREHENSIVE INCOME

                     Thirteen weeks ended September 2, 2000
                                   (unaudited)
                        (in thousands, except share data)

<TABLE>
<CAPTION>
                                       Class A             Class B                               Accumulated
                                     common stock        common stock      Additional                other                   Compre-
                                   ---------------     ---------------      paid-in   Retained   comprehensive               hensive
                                   Shares   Amount     Shares    Amount     capital   earnings   income (loss)      Total    income
                                   ------   ------     ------    ------     -------   --------   -------------      -----    ------
<S>                              <C>         <C>     <C>          <C>       <C>        <C>          <C>           <C>        <C>
Balance at June 3, 2000          4,015,111   $401    5,909,277    $591      $20,521    $59,852      $(1,331)      $80,034

Exercise of stock options                                2,825                   15                                    15
Income tax benefits on
  stock options exercised                                                         1                                     1
Compensation related to
  stock option plans                                                              1                                     1
Purchase of treasury stock            (842)            (20,837)     (2)        (145)                                 (147)
Net earnings                                                                             1,842                      1,842    $1,842
Unrealized holding loss on debt
  and equity securities                                                                              (1,238)       (1,238)   (1,238)
Foreign currency translation
  adjustments                                                                                           914           914       914
                                 ---------   ----    ---------    ----      -------    -------      -------       -------    ------
Comprehensive income                                                                                                         $1,518
                                                                                                                             ======
Balance at September 2, 2000     4,014,269   $401    5,891,265    $589      $20,393    $61,694      $(1,655)      $81,422
                                 =========   ====    =========    ====      =======    =======      =======       =======
</TABLE>

The accompanying notes are an integral part of this statement.


                                       -6-
<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (unaudited)
                                 (in thousands)


                                                        Thirteen weeks ended
                                                    ---------------------------
                                                    September 2,     August 28,
                                                       2000             1999
                                                     --------        --------

Cash flows from operating activities:
  Net earnings                                       $  1,842        $  1,798
  Adjustments to reconcile net earnings
    to net cash provided by operating
    activities
      Depreciation and amortization                       704             724
      Impairment of long-lived assets                     450
      Provision for doubtful accounts                      33              60
      Loss on sale of subsidiary and
        related assets                                    872
      Deferred income tax (benefit) provision          (1,731)             12
      Other non-cash items                                  1               1
      Changes in operating assets and
        liabilities, net of sale
          Accounts receivable                           1,076           1,745
          Inventories                                     210             169
          Other current assets                           (267)            175
          Other assets                                    (81)            (82)
          Accounts payable                               (264)           (326)
          Accrued liabilities                            (979)             30
          Accrued income taxes                            256             269
          Other noncurrent liabilities                     48              37
                                                     --------        --------

            Net cash provided by operating
              activities                                2,170           4,612
                                                     --------        --------

Cash flows from investing activities:
  Additions to property, plant and
    equipment, net                                       (851)           (438)
  Proceeds from sale of subsidiary and
    related assets                                      3,250
  Available-for-sale securities
    Purchases                                         (24,273)        (17,557)
    Proceeds from sale                                 17,960          13,960
                                                     --------        --------

      Net cash used in investing activities            (3,914)         (4,035)
                                                     --------        --------

Cash flows from financing activities:
  Repayments of debt                                      (61)           (792)
  Proceeds from exercise of stock options,
    including related income tax benefits                  16              46
  Purchase of treasury stock                             (147)           (172)
  Proceeds from issuance of stock in connection
    with the stock purchase plan                                            6
                                                     --------        --------

      Net cash used in financing activities              (192)           (912)
                                                     --------        --------


                                       -7-
<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

                CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)
                                   (unaudited)
                                 (in thousands)

<TABLE>
<CAPTION>
                                                                Thirteen weeks ended
                                                             --------------------------
                                                             September 2,    August 28,
                                                                 2000           1999
                                                               -------        -------
<S>                                                            <C>            <C>
Effect of exchange rate changes on
  cash and cash equivalents                                    $   (27)       $   (38)
                                                               -------        -------

      DECREASE IN CASH AND CASH
        EQUIVALENTS                                             (1,963)          (373)

Cash and cash equivalents
  Beginning of period                                            5,583          8,073
                                                               -------        -------

  End of period                                                $ 3,620        $ 7,700
                                                               =======        =======

Supplemental disclosures of cash flow information:
    Cash paid during the period for:
      Interest                                                 $    21        $    23
                                                               =======        =======

      Income taxes                                             $   511        $   600
                                                               =======        =======
</TABLE>

The accompanying notes are an integral part of these statements.


                                       -8-
<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

                      September 2, 2000 and August 28, 1999
                                   (unaudited)


NOTE A - CONSOLIDATED FINANCIAL STATEMENTS

     The  consolidated  balance sheet as of September 2, 2000, the  consolidated
     statement of stockholders'  equity and comprehensive  income for the period
     ended  September 2, 2000, and the  consolidated  statements of earnings and
     cash flows for the periods  ended  September  2, 2000 and August 28,  1999,
     have been prepared by the Company without audit. The  consolidated  balance
     sheet as of June 3, 2000 was derived  from audited  consolidated  financial
     statements.  In the opinion of management,  all adjustments  (which include
     only  normally  recurring  adjustments)  necessary  to  present  fairly the
     financial  position,  changes in  stockholders'  equity  and  comprehensive
     income,  results of operations and cash flows at September 2, 2000 (and for
     all periods presented) have been made.

     Certain  information  and  footnote   disclosures,   normally  included  in
     financial   statements  prepared  in  accordance  with  generally  accepted
     accounting principles, have been condensed or omitted. It is suggested that
     these  consolidated  financial  statements be read in conjunction  with the
     financial  statements and notes thereto  included in the fiscal 2000 Annual
     Report on Form 10-K filed by the Company on September 1, 2000.  The results
     of operations  for the periods ended  September 2, 2000 and August 28, 1999
     are not necessarily  indicative of the operating results for the respective
     full years.

     The consolidated  financial statements include the accounts of E-Z-EM, Inc.
     and  all  100%-owned   subsidiaries   (the   "Company").   All  significant
     intercompany balances and transactions have been eliminated.

NOTE B - EARNINGS PER COMMON SHARE

     Basic earnings per share are based on the weighted average number of common
     shares outstanding without consideration of potential common stock. Diluted
     earnings per share are based on the weighted  average  number of common and
     potential common shares outstanding. The calculation takes into account the
     shares that may be issued upon  exercise of stock  options,  reduced by the
     shares that may be  repurchased  with the funds received from the exercise,
     based on the average price during the period.

     The following table sets forth the  reconciliation  of the weighted average
     number of common shares:

                                                    Thirteen weeks ended
                                                  ------------------------
                                                  September 2,  August 28,
                                                      2000         1999
                                                     ------       ------
                                                       (in thousands)

          Basic                                       9,915       10,073
          Effect of dilutive securities
            (stock options)                             330          155
                                                     ------       ------

          Diluted                                    10,245       10,228
                                                     ======       ======


                                       -9-
<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

                      September 2, 2000 and August 28, 1999
                                   (unaudited)


NOTE B - EARNINGS PER COMMON SHARE (continued)

     Excluded from the calculation of earnings per common share,  are options to
     purchase  462,915 and 789,909  shares of common  stock at September 2, 2000
     and  August  28,  1999,  respectively,  as their  inclusion  would be anti-
     dilutive.

NOTE C - EFFECTS OF RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

     In  September  1998,  the  Financial   Accounting  Standards  Board  issued
     Statement of Financial  Accounting  Standards ("SFAS") No. 133, "Accounting
     for Derivative Instruments and Hedging Activities," which requires entities
     to recognize all derivatives in their financial statements as either assets
     or  liabilities  measured at fair value.  SFAS No. 133 also  specifies  new
     methods of accounting  for hedging  transactions,  prescribes the items and
     transactions  that may be hedged and specifies  detailed criteria to be met
     to qualify for hedge accounting.  SFAS No. 133, as amended by SFAS No. 137,
     is effective  for fiscal years  beginning  after  September  15, 2000.  The
     Company  currently does not use  derivative  instruments as defined by SFAS
     No. 133. If the Company  continues not to use these derivative  instruments
     by the effective  date of SFAS No. 133, the adoption of this  pronouncement
     will have no effect on the  Company's  results of  operations  or financial
     position.

NOTE D - COMPREHENSIVE INCOME

     The components of comprehensive income, net of related tax, are as follows:

<TABLE>
<CAPTION>
                                                                     Thirteen weeks ended
                                                                 ----------------------------
                                                                 September 2,      August 28,
                                                                     2000             1999
                                                                   -------          -------
                                                                        (in thousands)
<S>                                                                <C>              <C>
          Net earnings                                             $ 1,842          $ 1,798
          Unrealized holding loss on debt
            and equity securities                                   (1,238)            (179)
          Foreign currency translation
            adjustments                                                914             (217)
                                                                   -------          -------

              Comprehensive income                                 $ 1,518          $ 1,402
                                                                   =======          =======
</TABLE>

     The components of accumulated  other  comprehensive  income (loss),  net of
     related tax, are as follows:

<TABLE>
<CAPTION>
                                                                 September 2,        June 3,
                                                                     2000             2000
                                                                   -------          -------
                                                                        (in thousands)
<S>                                                                <C>              <C>
          Unrealized holding gain on debt
            and equity securities                                  $   826          $ 2,064
          Cumulative translation adjustments                        (2,481)          (3,395)
                                                                   -------          -------

              Accumulated other comprehensive income
                (loss)                                             $(1,655)         $(1,331)
                                                                   =======          =======
</TABLE>


                                      -10-
<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

                      September 2, 2000 and August 28, 1999
                                   (unaudited)


NOTE E - SALE OF SUBSIDIARY AND RELATED ASSETS

     On July 27, 2000,  AngioDynamics,  Inc. entered into two agreements to sell
     all the capital stock of AngioDynamics Ltd., a wholly-owned subsidiary, and
     certain  other assets to  AngioDynamics  Ltd.'s  management.  AngioDynamics
     Ltd.,  located in Ireland,  manufactured  cardiovascular and interventional
     radiology  products.  The aggregate  consideration  paid was  $3,250,000 in
     cash. The sale was the culmination of AngioDynamics'  strategic decision to
     exit the cardiovascular  market and to focus entirely on the interventional
     radiology  marketplace.  As a result of this sale, the Company recognized a
     pre-tax loss of  approximately  $872,000 during the quarter ended September
     2, 2000. The aforementioned  pre-tax loss includes the effect of previously
     unrealized losses on foreign currency translation of approximately $994,000
     and the write-off of  approximately  $673,000 in inventory and  intangibles
     related to the  cardiovascular  product  line,  both of which were non-cash
     charges.  Further,  AngioDynamics entered into a manufacturing agreement, a
     distribution  agreement and a royalty  agreement with the buyer.  Under the
     two-year manufacturing  agreement,  the buyer will be manufacturing certain
     interventional radiology products sold by AngioDynamics.

NOTE F - ASSET IMPAIRMENT CHARGE

     In  accordance  with  SFAS  No.  121,  "Accounting  for the  Impairment  of
     Long-Lived  Assets  and for  Long-Lived  Assets  to be  Disposed  Of,"  the
     Company's Diagnostic operating segment recorded an impairment charge during
     the  quarter  ended  September  2, 2000 of  $450,000  relating  to  certain
     acquired  patent  rights to an oral  magnetic  resonance  imaging  contrast
     agent. The Company determined that the revenue potential of this technology
     was impaired,  since it now believes that the market for this technology is
     significantly  less  than  previously  projected.   The  impairment  charge
     represents  the  difference  between the carrying  value of the  intangible
     asset and the fair  market  value of this asset based on  estimated  future
     discounted cash flows.  The charge had no impact on the Company's cash flow
     or its ability to generate cash flow in the future.  The impairment  charge
     is included in the  consolidated  statement  of earnings  under the caption
     "Selling and administrative".

NOTE G - INVENTORIES

     Inventories consist of the following:

                                        September 2,         June 3,
                                            2000              2000
                                          -------           -------
                                               (in thousands)

          Finished goods                  $12,948           $13,246
          Work in process                   2,115             2,813
          Raw materials                    10,303            10,797
                                          -------           -------

                                          $25,366           $26,856
                                          =======           =======


                                      -11-
<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

                      September 2, 2000 and August 28, 1999
                                   (unaudited)


NOTE H - INCOME TAXES

     During the thirteen weeks ended  September 2, 2000, the Company reduced its
     valuation   allowance   primarily  to  recognize  deferred  tax  assets  of
     approximately  $1,344,000.  Continued and projected future profitability of
     the Company's U.S.  operations,  including those of AngioDynamics,  made it
     more likely than not that  certain  deferred  tax assets  would be realized
     through future taxable earnings.

NOTE I - COMMON STOCK

     Under the 1983 and 1984 Stock Option  Plans,  options for 2,825 shares were
     exercised  at prices  ranging  from $4.31 to $5.63 per share,  options  for
     7,449  shares  were  forfeited  at prices  ranging  from $5.39 to $5.63 per
     share,  and no options  were granted or expired  during the thirteen  weeks
     ended September 2, 2000.  Under the 1997  AngioDynamics  Stock Option Plan,
     options for .63 shares were forfeited at $40,000 per share,  and no options
     were  granted,  exercised  or  expired  during  the  thirteen  weeks  ended
     September 2, 2000.

     In January 1999, the Board of Directors  authorized the repurchase of up to
     500,000  shares  of the  Company's  Class B Common  Stock  at an  aggregate
     purchase price of up to $2,000,000. In October 1999, the Board modified the
     program to include the Company's  Class A Common Stock.  In February  2000,
     the Board further  modified the program to increase the aggregate  purchase
     price of Class A and Class B Common Stock by an additional  $2,000,000.  As
     of September 2, 2000, the Company had repurchased  38,987 shares of Class A
     Common Stock and 334,585  shares of Class B Common Stock for  approximately
     $2,650,000.

NOTE J - OPERATING SEGMENTS

     In fiscal  1999,  the  Company  adopted  SFAS No. 131,  "Disclosures  about
     Segments of an Enterprise and Related Information". The statement redefines
     how operating  segments are determined  and requires  disclosure of certain
     financial and descriptive information about a company's operating segments.

     The  Company is  engaged  in the  manufacture  and  distribution  of a wide
     variety of  products  which are  classified  into two  operating  segments:
     Diagnostic  products  and  AngioDynamics   products.   Diagnostic  products
     encompass both contrast systems,  consisting of barium sulfate formulations
     and related medical devices used in X-ray, CT-scanning,  ultrasound and MRI
     imaging  examinations,  and non-contrast  systems,  including  radiological
     medical   devices,   custom  contract   pharmaceuticals,   gastrointestinal
     cleansing  laxatives,  X-ray protection  equipment,  and immunoassay tests.
     AngioDynamics  products include  angiographic,  thrombolytic,  image-guided
     vascular access, angioplasty,  stents, and drainage medical devices used in
     the interventional radiology marketplace.


                                      -12-
<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

                      September 2, 2000 and August 28, 1999
                                   (unaudited)


NOTE J - OPERATING SEGMENTS (continued)

     The Company's chief operating decision maker utilizes operating segment net
     earnings  (loss)  information in assessing  performance  and making overall
     operating  decisions  and  resource  allocations.   Information  about  the
     Company's segments is as follows:

<TABLE>
<CAPTION>
                                                              Thirteen weeks ended
                                                          ---------------------------
                                                          September 2,     August 28,
                                                              2000            1999
                                                           ---------       ---------
                                                                 (in thousands)
<S>                                                        <C>             <C>
          Net sales to external customers
            Diagnostic products
              Contrast systems                             $  15,615       $  16,027
              Non-contrast systems                             6,088           6,829
                                                           ---------       ---------

              Total Diagnostic products                       21,703          22,856
            AngioDynamics products                             5,601           4,341
                                                           ---------       ---------

          Total net sales to external customers            $  27,304       $  27,197
                                                           =========       =========

          Intersegment net sales
            Diagnostic products                            $      --       $     191
            AngioDynamics products                               190             158
                                                           ---------       ---------

          Total intersegment net sales                     $     190       $     349
                                                           =========       =========

          Operating profit (loss)
            Diagnostic products                            $   1,227       $   2,929
            AngioDynamics products                              (550)           (408)
            Eliminations                                         (48)             24
                                                           ---------       ---------

          Total operating profit                           $     629       $   2,545
                                                           =========       =========

          Net earnings (loss)
            Diagnostic products                            $   1,184       $   2,310
            AngioDynamics products                               706            (536)
            Eliminations                                         (48)             24
                                                           ---------       ---------

          Total net earnings                               $   1,842       $   1,798
                                                           =========       =========
</TABLE>

<TABLE>
<CAPTION>
                                                          September 2,       June 3,
                                                              2000            2000
                                                           ---------       ---------
                                                                (in thousands)
<S>                                                        <C>             <C>
          Assets
            Diagnostic products                            $ 109,447       $ 111,046
            AngioDynamics products                            17,294          17,573
            Eliminations                                     (27,815)        (29,534)
                                                           ---------       ---------

          Total assets                                     $  98,926       $  99,085
                                                           =========       =========
</TABLE>


                                      -13-
<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

                      MANAGEMENT'S DISCUSSION AND ANALYSIS
                OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS


Quarters ended September 2, 2000 and August 28, 1999
----------------------------------------------------

     The  Company's  quarters  ended  September 2, 2000 and August 28, 1999 both
represent thirteen weeks.

Results of Operations
---------------------

     Segment Overview
     ----------------

     The Company  operates in two  industry  segments:  Diagnostic  products and
AngioDynamics  products. The Diagnostic products operating segment includes both
contrast systems and non-contrast systems. The AngioDynamics  products operating
segment includes  angiographic  products,  thrombolytic  products,  image-guided
vascular access products,  angioplasty  products,  stents, and drainage products
used in the interventional radiology marketplace.

<TABLE>
<CAPTION>
                                           Diagnostic    AngioDynamics      Eliminations        Total
                                           ----------    -------------      ------------        -----
                                                                  (in thousands)
<S>                                          <C>             <C>                 <C>           <C>
Quarter ended September 2, 2000
-------------------------------

    Unaffiliated customer sales              $21,703         $ 5,601             --            $27,304
    Intersegment sales                          --               190            ($190)            --
    Gross profit (loss)                        9,349           2,802              (48)          12,103
    Operating profit (loss)                    1,227            (550)             (48)             629

Quarter ended August 28, 1999
-----------------------------

    Unaffiliated customer sales              $22,856         $ 4,341             --            $27,197
    Intersegment sales                           191             158            ($349)            --
    Gross profit                              10,045           2,015               23           12,083
    Operating profit (loss)                    2,929            (408)              24            2,545
</TABLE>

     Diagnostic Products
     -------------------

     Diagnostic  segment  operating  results for the current quarter declined by
$1,702,000  due  primarily  to decreased  sales and gross  profit and  increased
operating expenses.  Net sales decreased 5%, or $1,153,000,  due to lower demand
for sales of both  contrast  systems and  non-contrast  systems.  The decline in
sales of  non-contrast  systems  resulted from decreased  custom contract sales.
Price  increases  accounted  for  approximately  2% of net sales for the current
quarter. Gross profit expressed as a percentage of net sales declined to 43% for
the current quarter,  from 44% for the comparable  quarter of the prior year due
primarily to decreased production throughput, partially offset by the effects of
sales  price  increases.  Increased  operating  expenses  of  $1,006,000  can be
attributed,  in large part,  to: an  impairment  charge of $450,000  relating to
acquired  patent rights to an oral magnetic  resonance  imaging  contrast agent;
increased costs  associated with foreign  product  registrations;  and increased
administrative expenses.

     AngioDynamics Products
     ----------------------

     AngioDynamics  segment  operating  results for the current  quarter,  which
declined by $142,000, were adversely affected by the sale of AngioDynamics Ltd.,
a wholly-owned subsidiary, and certain other assets. AngioDynamics Ltd., located
in Ireland, manufactured cardiovascular and interventional radiology products.


                                      -14-
<PAGE>

The sale was the culmination of  AngioDynamics'  strategic  decision to exit the
cardiovascular  market and to focus  entirely  on the  interventional  radiology
marketplace.  As a result of this sale, the Company recognized a pre-tax loss of
approximately   $872,000  during  the  quarter  ended  September  2,  2000.  The
aforementioned  pre-tax loss includes the effect of previously unrealized losses
on foreign currency  translation of approximately  $994,000 and the write-off of
approximately   $673,000   in   inventory   and   intangibles   related  to  the
cardiovascular product line, both of which were non-cash charges.

     Excluding  the  loss  on  sale,  AngioDynamics  segment  operating  results
improved by $730,000 due to increased sales and improved gross profit. Net sales
increased  29%,  or  $1,260,000,  due,  in large  part,  to sales of several new
products, namely Abscession(TM) fluid drainage catheters, VistaFlex(TM) platinum
biliary  stents,  and  Workhorse(TM)  PTA balloon  catheters,  introduced in the
second  quarter of last fiscal year.  Gross profit  expressed as a percentage of
net sales  improved to 48% for the current  quarter from 45% for the  comparable
quarter of the prior year due primarily to increased  production  throughput and
changes in product mix.

     Consolidated Results of Operations
     ----------------------------------

     For the quarter ended September 2, 2000, the Company  reported net earnings
of  $1,842,000,  or $.19 and $.18 per common share on a basic and diluted basis,
respectively,  as compared to net  earnings  of  $1,798,000,  or $.18 per common
share on both a basic and diluted basis for the comparable  period of last year.
Results  for the  current  quarter  were  favorably  affected  by the  Company's
reversal  of a portion of its income tax  valuation  allowance  against  certain
domestic tax benefits totaling $1,344,000,  since it is now more likely than not
that such  benefits  will be  realized.  Results  for the current  quarter  were
adversely affected by increased operating expenses of $1,936,000,  due, in large
part, to the loss on sale of  AngioDynamics  Ltd. and related assets of $872,000
and the Diagnostic asset impairment charge of $450,000.

     Net sales for the quarter ended  September 2, 2000  increased less than 1%,
or $107,000,  as compared to the quarter ended August 28, 1999.  Increased sales
of  AngioDynamics  products of $1,260,000 were offset by decreased sales of non-
contrast  systems of $741,000 and contrast  systems of $412,000.  The decline in
sales of  non-contrast  systems  resulted from decreased  custom contract sales.
Price increases  accounted for approximately 1 1/2% of net sales for the current
quarter. Net sales in international  markets,  including direct exports from the
U.S., decreased 14%, or $1,409,000,  for the current quarter from the comparable
period  of last  year  due  primarily  to  decreased  custom  contract  sales of
$1,195,000.  Continued  weakness of the Euro  compared  to the U.S.  dollar also
contributed  to  sluggish   international   sales,  as  the  Company's  domestic
operations bill export sales in U.S. dollars.

     Gross profit  expressed  as a percentage  of net sales was 44% for both the
current quarter as well as the comparable quarter of the prior year, as improved
gross profit in the AngioDynamics  segment was offset by reduced gross profit in
the Diagnostic segment.  The improved  AngioDynamics gross profit expressed as a
percentage of net sales was due primarily to increased production throughput and
changes in product mix. The decline in  Diagnostic  gross profit  expressed as a
percentage of net sales resulted primarily from decreased production throughput,
partially offset by the effects of sales price increases.

     Selling and administrative ("S&A") expenses were $9,330,000 for the quarter
ended  September 2, 2000 compared to $8,337,000 for the quarter ended August 28,
1999.  This  increase  of  $993,000,  or 12%,  for the  current  quarter was due
primarily to increased  Diagnostic  S&A expenses,  which can be  attributed,  in
large  part,  to the  asset  impairment  charge  of  $450,000,  increased  costs
associated  with foreign  product  registrations,  and increased  administrative
expenses.


                                      -15-
<PAGE>

     Research and development ("R&D") expenditures  increased 6% for the current
quarter to $1,272,000,  or 5% of net sales, from $1,201,000, or 4% of net sales,
for the comparable quarter of the prior year due to increased general regulatory
costs. Of the R&D expenditures for the current quarter, approximately 42% relate
to  contrast  systems,  29%  to  AngioDynamics  projects,  5%  to  immunological
projects,  6% to  other  projects  and  18% to  general  regulatory  costs.  R&D
expenditures are expected to continue at approximately current levels.

     Other income,  net of other  expenses,  totaled  $173,000 of income for the
current quarter compared to $165,000 of income for the comparable period of last
year.  Increased  interest  income of $81,000,  resulting from the investment of
additional  funds provided by operations,  offset a decline in foreign  currency
exchange gains and losses of $70,000.

     For the quarter ended September 2, 2000, the Company reported an income tax
benefit of  $1,040,000  against  earnings  before  income  taxes of $802,000 due
primarily  to the fact that the  Company  reversed  a portion  of its  valuation
allowance against certain domestic tax benefits totaling  $1,344,000.  Continued
and projected future profitability of the Company's U.S.  operations,  including
those of  AngioDynamics,  made it more likely than not that certain deferred tax
assets  would  be  realized  through  future  taxable  earnings.  The  Company's
effective  tax rate for the  quarter  ended  August 28,  1999  approximated  the
Federal  statutory tax rate of 34%.  Losses  incurred in a foreign  jurisdiction
subject to lower tax rates were offset by earnings of the Company's Puerto Rican
subsidiary, which are subject to favorable U.S. tax treatment.

Liquidity and Capital Resources
-------------------------------

     For the quarter ended September 2, 2000, capital expenditures, the purchase
of  treasury  stock  and  debt  repayments  were  funded  by  cash  provided  by
operations.  The Company's policy has been to fund capital  requirements without
incurring  significant debt. At September 2, 2000, debt (notes payable,  current
maturities of long-term  debt and long-term  debt) was $1,607,000 as compared to
$1,636,000 at June 3, 2000. The Company has available  $3,357,000 under two bank
lines of credit of which no amounts were outstanding at September 2, 2000.

     At September 2, 2000,  approximately  65% of the Company's assets consisted
of inventories,  accounts receivable, short-term debt and equity securities, and
cash and cash  equivalents.  The  current  ratio was 4.80 to 1, with net working
capital of $54,895,000,  at September 2, 2000, as compared to a current ratio of
4.25 to 1, with net working capital of $51,434,000, at June 3, 2000.

     In January 1999, the Board of Directors  authorized the repurchase of up to
500,000  shares of the Company's  Class B Common Stock at an aggregate  purchase
price of up to  $2,000,000.  In October 1999,  the Board modified the program to
include the Company's  Class A Common Stock. In February 2000, the Board further
modified the program to increase  the  aggregate  purchase  price of Class A and
Class B Common Stock by an additional  $2,000,000.  As of September 2, 2000, the
Company had repurchased 38,987 shares of Class A Common Stock and 334,585 shares
of Class B Common Stock for approximately $2,650,000.

     Forward-Looking Statements
     --------------------------

     This Form 10-Q  contains  certain  forward-looking  statements  within  the
meaning  of  Section  27A of  the  Securities  Act  of  1933,  as  amended  (the
"Securities  Act"),  and Section 21E of the Securities  Exchange Act of 1934, as
amended  (the  "Exchange  Act"),  which are  intended  to be covered by the safe
harbors  created  thereby.  Words such as "expects",  "intends",  "anticipates",
"plans",  "believes",  "seeks",  "estimates",  or  variations  of such words and
similar  expressions are intended to identify such  forward-looking  statements.
Investors are cautioned that all  forward-looking  statements  involve risks and
uncertainty, including without limitation, the ability of the Company to develop
its products, future


                                      -16-
<PAGE>

actions by the U.S. Food and Drug  Administration or other regulatory  agencies,
results  of  pending  or  future  clinical  trials,  as well as  general  market
conditions,  competition  and pricing.  Although the Company  believes  that the
assumptions  underlying  the  forward-looking  statements  contained  herein are
reasonable, any of the assumptions could be inaccurate, and therefore, there can
be no assurance that the  forward-looking  statements included in this Form 10-Q
will prove to be accurate. In light of the significant uncertainties inherent in
the   forward-looking   statements   included  herein,  the  inclusion  of  such
information  should not be  regarded as a  representation  by the Company or any
other person that the objectives and plans of the Company will be achieved.

     Effects of Recently Issued Accounting Pronouncements
     ----------------------------------------------------

     In September 1998, the Financial Accounting Standards Board issued SFAS No.
133,  "Accounting  for Derivative  Instruments  and Hedging  Activities,"  which
requires entities to recognize all derivatives in their financial  statements as
either assets or liabilities measured at fair value. SFAS No. 133 also specifies
new methods of accounting  for hedging  transactions,  prescribes  the items and
transactions  that may be hedged and  specifies  detailed  criteria to be met to
qualify  for hedge  accounting.  SFAS No.  133,  as amended by SFAS No.  137, is
effective  for fiscal years  beginning  after  September  15, 2000.  The Company
currently does not use derivative instruments as defined by SFAS No. 133. If the
Company continues not to use these derivative  instruments by the effective date
of SFAS No. 133, the adoption of this  pronouncement  will have no effect on the
Company's results of operations or financial position.

Item 3. Quantitative and Qualitative Disclosures About Market Risk
        ----------------------------------------------------------

     The  Company  is exposed to market  risk from  changes in foreign  currency
exchange rates and, to a much lesser extent,  interest rates on investments  and
financing,  which could impact results of operations and financial position. The
Company does not  currently  engage in hedging or other  market risk  management
tools.  There  have  been no  material  changes  with  respect  to  market  risk
previously disclosed in the fiscal 2000 Annual Report on Form 10-K.

     Foreign Currency Exchange Rate Risk
     -----------------------------------

     The Company's  international  subsidiaries  are  denominated  in currencies
other than the U.S.  dollar.  Since the  functional  currency  of the  Company's
international  subsidiaries is the local currency,  foreign currency translation
adjustments  are accumulated as a component of accumulated  other  comprehensive
income (loss) in stockholders' equity.  Assuming a hypothetical aggregate change
in the  foreign  currencies  versus  the U.S.  dollar  exchange  rates of 10% at
September  2, 2000,  the  Company's  assets and  liabilities  would  increase or
decrease by $2,065,000 and $553,000,  respectively,  and the Company's net sales
and  net  earnings  would  increase  or  decrease  by  $1,936,000  and  $72,000,
respectively, on an annual basis.

     The Company also maintains  intercompany balances and loans receivable with
subsidiaries  with  different  local  currencies.  These  amounts are at risk of
foreign  exchange  losses if exchange rates  fluctuate.  Assuming a hypothetical
aggregate change in the foreign currencies versus the U.S. dollar exchange rates
of 10% at  September  2,  2000,  results of  operations  would be  favorably  or
unfavorably impacted by approximately $514,000 on an annual basis.

     Interest Rate Risk
     ------------------

     The Company is exposed to interest  rate change market risk with respect to
its investments in tax-free  municipal  bonds in the amount of $14,305,000.  The
bonds bear interest at a floating rate established weekly. For the quarter


                                      -17-
<PAGE>

ended September 2, 2000, the after-tax  interest rate on the bonds  approximated
4.3%.  Each 100 basis point (1%)  fluctuation in interest rates will increase or
decrease  interest  income on the bonds by  approximately  $143,000 on an annual
basis.

     As  the  Company's  principal  amount  of  fixed  interest  rate  financing
approximated  $1,607,000 at September 2, 2000, a change in interest  rates would
not materially impact results of operations or financial position.  At September
2, 2000, the Company did not maintain any variable interest rate financing.


                                      -18-
<PAGE>

                          E-Z-EM, Inc. and Subsidiaries

                           Part II: Other Information


Item 6. Exhibits and Reports on Form 8-K
        --------------------------------

(a)     Exhibits
        --------
        No.         Description                                            Page
        ---         -----------                                            ----

        27     Financial data schedule                                      20

(b)     Reports on Form 8-K
        -------------------

        No reports on Form 8-K were filed during the quarter ended  September 2,
        2000.


                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.



                                         E-Z-EM, Inc.
                                         -------------------------------------
                                         (Registrant)




Date   October 13, 2000                  /s/ Anthony A. Lombardo
     --------------------                -------------------------------------
                                         Anthony A. Lombardo, President,
                                         Chief Executive Officer and Director




Date   October 13, 2000                  /s/ Dennis J. Curtin
     --------------------                -------------------------------------
                                         Dennis J. Curtin, Senior Vice
                                         President - Chief Financial Officer
                                         (Principal Financial and Chief
                                         Accounting Officer)


                                      -19-